Canaccord Genuity analyst Neil Maruoka likes the recent developments at ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News: TSX:PLI).
This morning, ProMetic announced that Ryplazim, its plasminogen replacement therapy for the treatment of patients with congenital plasminogen deficiency, had received a Pediatric Disease designation.
“We are pleased that Ryplazim has received this pediatric designation from the FDA. In addition to Ryplazim’s orphan drug status, this designation represents another validation of the approach we have taken regarding our plasminogen’s clinical program,” said CEO Pierre Laurin. “The pediatric designation also provides an important incentive for ProMetic to continue developing therapies addressing unmet medical needs for children with rare diseases. We look forward to continue to work closely with the FDA to bringing this innovative therapy to patients suffering from plasminogen deficiency.”
Maruoka today explained the significance of this news, and adds that he thinks Ryplazim still has a good chance of approval, noting that the Ryplazim BLA issupported by strong clinical data, Orphan Drug status, an Accelerated Approval pathway, and now a Pediatric Disease designation
“A Priority Review voucher reduces the review time for any drug from 10 months to 6 months; it is transferable and they have been sold in the past for over $100 million,” the analyst notes. “We believe this would be a valuable asset for ProMetic, with the potential to help alleviate the financing overhang. Nonetheless, we believe that the process of monetizing a Priority Review voucher could take some time, and we therefore remain cautious of ProMetic’s cash burn.”
In a research update to clients today, Maruoka maintained his “Buy” rating and one-year price target of $4.25 on ProMetic, implying a return of 254.2 per cent.
Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]
Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]
Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]
With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]
The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]
Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]